Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Liabilities and Shareholders Equity (2019 - 2026)

Opus Genetics has reported Liabilities and Shareholders Equity over the past 13 years, most recently at $66.8 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 38.66% to $66.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $191.8 million through Mar 2026, up 12.67% year-over-year, with the annual reading at $50.2 million for FY2025, 36.3% up from the prior year.
  • Liabilities and Shareholders Equity was $66.8 million for Q1 2026 at Opus Genetics, up from $50.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $66.8 million in Q1 2026 and troughed at $14.6 million in Q3 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $44.8 million (2024), against an average of $41.9 million.
  • Year-over-year, Liabilities and Shareholders Equity tumbled 37.22% in 2022 and then surged 271.99% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $49.0 million in 2022, then rose by 10.12% to $53.9 million in 2023, then crashed by 31.67% to $36.9 million in 2024, then skyrocketed by 36.3% to $50.2 million in 2025, then soared by 32.93% to $66.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Liabilities and Shareholders Equity are $66.8 million (Q1 2026), $50.2 million (Q4 2025), and $36.1 million (Q3 2025).